• news
    • Press releases
    • Blog
    • Media Coverage
    • Event
  • Documents
  • About
  • Team
  • funds
    • o2h human health KI EIS
    • o2h human health SEIS
    • o2h human health EIS
  • Portfolio
  • knowledgehub
    • what is KI EIS fund?
  • Contact

o2h-ventures

  • news
    • Press releases
    • Blog
    • Media Coverage
    • Event
  • Documents
  • About
  • Team
  • funds
    • o2h human health KI EIS
    • o2h human health SEIS
    • o2h human health EIS
  • Portfolio
  • knowledgehub
    • what is KI EIS fund?
  • Contact

Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment and you are unlikely to be protected if something goes wrong. Take 2 mins to learn more

o2h Ventures Wins Best EIS Investment Manager – Specialist at Growth Investor Awards 2024
o2h Ventures Wins Best EIS Investment Manager – Specialist at Growth Investor Awards 2024
Dec 1 2024

Cambridge, UK

We are thrilled to announce that o2h Ventures has been recognised as the Best EIS Investment Manager — Specialist at the 10th annual Growth Investor Awards.

Hosted by Intelligent Partnership, this year’s Growth Investor Awards mark a decade of celebrating UK SME investment opportunities. These awards shine a spotlight on companies and individuals who go above and beyond to support the UK’s burgeoning businesses, fostering job creation, driving economic growth, and championing innovation.

The Best EIS Manager-Specialist category recognises investment managers specialising in Enterprise Investment Schemes (EIS) with a particular focus area on impactful underlying investments. The judging panel seeks funds and firms that use investment as a force for good., applauding both traditional growth metrics as well as impact metrics. 

As a leading biotech specialist tax-efficient fund manager, o2h Ventures is dedicated to supporting and nurturing early-stage biotech companies in the United Kingdom. To date, we have invested in 35 portfolio companies, working on impactful areas of high unmet medical needs, including cancer, depression, diseases of the ear and eye, psoriasis, idiopathic pulmonary fibrosis, anti-ageing, and infectious diseases. This award acknowledges our unwavering passion for nurturing the biotech ecosystem and for being a true investment specialist. 

Learn more about our fund offerings at o2hventures.com/funds. 

About the Growth Investor Awards 2024

The Growth Investor Awards are bigger than ever this year, with over 20 categories and more than 75 opportunities to win an accolade.

Guy Tolhurst, Managing Director of Intelligent Partnership, commented:

 “Our finalists this year have truly set new standards for the growth investment community. We are consistently amazed by the crucial contributions our finalists make in supporting the UK’s most rapidly expanding SMEs and startups. The competition is always fierce, but this year has surpassed all our expectations. O2h Ventures] deserves immense congratulations for reaching the final in the Best EIS Investment Manager—Special, as the competition was exceptionally tough.”

ENDS

Connect with us
  • linkedin
  • youtube
  • email
o2h-ventures
recent press releases
  • o2h-ventures o2h Ventures Invests in Revolver Therapeutics Revolutionising Childhood Cancer Treatment 10 Dec 2024
  • o2h-ventures o2h Ventures Portfolio Company ViaNautis Enters Strategic Collaboration Agreement with Eli Lilly to Accelerate Genetic Medicine Development 30 Oct 2024
  • o2h-ventures o2h Ventures, Third-Time Finalist in the Best EIS Manager Specialist at the Growth Investor Awards 2024 09 Aug 2024
o2h-ventures
o2h Ventures Limited
Hauxton House,
The Mill SciTech Park,
Mill Lane, Hauxton
Cambridge
CB22 5HX
07341612481
invest@o2h.com
about
  • about us
  • team
  • portfolio
  • funds
insights and news
  • knowledge hub
  • press releases
  • blog
  • event
  • documents
connect with us
  • linkedin
  • youtube
  • email
Please refer to the relevant fund’s full risk warnings contained in their Information Memorandums.
Your capital is at risk. Investing in early stage businesses involves risks, including illiquidity, lack of dividends, loss of investment and dilution, and it should be done only as part of a diversified portfolio. o2h Ventures’ funds are targeted exclusively at sophisticated or high net worth investors who understand these risks and make their own investment decisions. Tax relief depends on an individual’s circumstances and may change in the future. In addition, the availability of tax relief depends on the company invested in maintaining its qualifying status. Past performance is not a reliable indicator of future performance. You should not rely on any past performance as a guarantee of future investment performance.
o2h ventures Limited is regulated and authorised by the Financial Conduct Authority (FRN 812245). Capital at risk, only suitable for high net worth and sophisticated investors
© 2025 o2h ventures
  • Privacy Policy
  • Blog
  • Contact us

Risk Information

Due to the potential for losses, the Financial Conduct Authority (FCA) considers this investment to be high risk

What are the key risks?

1 – You could lose all the money you invest

• If the business you invest in fails, you are likely to lose 100% of the money you invest. Most start-up businesses fail.

2 – You are unlikely to be protected if something goes wrong

• Protection from the Financial Services Compensation Scheme (FSCS), in relation to claims against failed regulated firms, does not cover poor investment performance. Try the FSCS investment protection checker here. (https://www.fscs.org.uk/check/investment-protection-checker)

• Protection from the Financial Ombudsman Service (FOS) does not cover poor investment performance. If you have a complaint against an FCA-regulated firm, FOS may be able to consider it. Learn more about FOS protection here. (https://www.financial-ombudsman.org.uk/consumers)

3 – You won’t get your money back quickly

• Even if the business you invest in is successful, it may take several years to get your money back. You are unlikely to be able to sell your investment early.

• The most likely way to get your money back is if the business is bought by another business or lists its shares on an exchange such as the London Stock Exchange. These events are not common.

• If you are investing in a start-up business, you should not expect to get your money back through dividends. Start-up businesses rarely pay these.

4 – Don’t put all your eggs in one basket

• Putting all your money into a single business or type of investment for example, is risky. Spreading your money across different investments makes you less dependent on any one to do well.

• A good rule of thumb is not to invest more than 10% of your money in high-risk investments (https://www.fca.org.uk/investsmart/5-questions-ask-you-invest)

5 – The value of your investment can be reduced

• The percentage of the business that you own will decrease if the business issues more shares. This could mean that the value of your investment reduces, depending on how much the business grows. Most start-up businesses issue multiple rounds of shares.

• These new shares could have addition rights that your shares don’t have, such as the right to receive a fixed dividend, which could further reduce your chances of getting a return on your investment.

If you are interested in learning more about how to protect yourself, visit the FCA’s website here (https://www.fca.org.uk/investsmart)